Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study

Inclusion Criteria: * Pre-menopausal * Regular, consistent menstrual cycles * Serum progesterone \> 6 ng/ml (19 nmol/L) * 2 months history of PBLAC score of 150-500 * Maximum of 4 type I, type II, or intramural fibroids * Patient is at low risk for cervical cancer * Hemoglobin \> 6 g/dl * Not at risk for pregnancy * No desire for future fertility * Willing and able to complete the follow-up requirements outlined in the study design section of the protocol * Willing to sign a consent form Exclusion Criteria: * Subserosal fibroids. * Any fibroid that obstructs access to the endometrial cavity * FSH \> 20 IU/L * Pregnancy * Evidence of disorders of hemostasis * Use of GnRH agonist or depomedroxyprogesterone acetate or other implantable or injectable progestin and/or estrogen * SERMS/SPRMS within the last 6 months * Current use of any IUD or use of Mirena IUS within the last 3 months * Gynecological malignancy or hyperplasia * Known/suspected abdominal/pelvic cancer * Active pelvic infection (e.g., active salpingitis or other pelvic inflammatory disease) * Adenomyosis * Previous surgical or ablative treatment for fibroids or menorrhagia * Previous uterine artery embolization or occlusion * Patient on anti-coagulation therapy * Needing emergency surgery to treat fibroid symptoms * Concomitant intrauterine polyps. * Major medical or psychiatric illness affecting general health or patient's ability to comply with follow-up schedule or provide valid patient self-assessment data * Contraindication to MRI * Allergy to contrast media * Mild renal insufficiency or worse * Known renal disease * Uncontrolled hypertension lasting 2 years or more * Diabetes * Uterine size \> 10 weeks or 10 cm from ectocervix to fundus.